EICHOR
● Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Condition: Extensive Stage Small Cell Lung Cancer · Sponsor: Amgen
About this study
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
This description comes directly from the study's public registry record.
Talk to the study team
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
Locations (19)
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| University of Southern California, Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Norton Cancer Institute - Downtown | Louisville, Kentucky, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Allegheny General Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| Avera Cancer Institute | Sioux Falls, South Dakota, United States | Recruiting |
| Baptist Cancer Center | Memphis, Tennessee, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07037758